Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H26N2O3 |
| Molecular Weight | 330.4213 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2NC(=CC2=C1)C(=O)N3CCC(CC(C)(C)O)CC3
InChI
InChIKey=OXSCPDKUZWPWFR-UHFFFAOYSA-N
InChI=1S/C19H26N2O3/c1-19(2,23)12-13-6-8-21(9-7-13)18(22)17-11-14-10-15(24-3)4-5-16(14)20-17/h4-5,10-11,13,20,23H,6-9,12H2,1-3H3
| Molecular Formula | C19H26N2O3 |
| Molecular Weight | 330.4213 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:55:26 GMT 2023
by
admin
on
Sat Dec 16 18:55:26 GMT 2023
|
| Record UNII |
AA79G37CPR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000042376
Created by
admin on Sat Dec 16 18:55:26 GMT 2023 , Edited by admin on Sat Dec 16 18:55:26 GMT 2023
|
PRIMARY | |||
|
25210792
Created by
admin on Sat Dec 16 18:55:26 GMT 2023 , Edited by admin on Sat Dec 16 18:55:26 GMT 2023
|
PRIMARY | |||
|
AA79G37CPR
Created by
admin on Sat Dec 16 18:55:26 GMT 2023 , Edited by admin on Sat Dec 16 18:55:26 GMT 2023
|
PRIMARY | |||
|
ASP-9521
Created by
admin on Sat Dec 16 18:55:26 GMT 2023 , Edited by admin on Sat Dec 16 18:55:26 GMT 2023
|
PRIMARY | MedKoo CAT NO: 205818; CAS NO: 1126084-37-4; Description: ASP9521 is a novel, selective, orally bioavailable inhibitor of 17.BETA.-hydroxysteroid dehydrogenase type 5 (17.BETA.HSD5AKR1C3). ASP9521 has demonstrated anti-tumour activity in in vitro and in vivo preclinical models. ASP9521 inhibited conversion of androstenedione (AD) into testosterone (T) by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L - IC50,monkey: 49 nmol/L). ASP9521 showed >100-fold selectivity for AKR1C3 over the isoform AKR1C2. In LNCaP-AKR1C3 cells, ASP9521 suppressed AD-dependent PSA production and cell proliferation. In patients with mCRPC, ASP9521 demonstrated dose-proportional increase in exposure over the doses evaluated, with an acceptable safety and tolerability profile. However, the novel androgen biosynthesis inhibitor showed no relevant evidence of clinical activity. (Last update: 11/18/2015). | ||
|
C133224
Created by
admin on Sat Dec 16 18:55:26 GMT 2023 , Edited by admin on Sat Dec 16 18:55:26 GMT 2023
|
PRIMARY | |||
|
1126084-37-4
Created by
admin on Sat Dec 16 18:55:26 GMT 2023 , Edited by admin on Sat Dec 16 18:55:26 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Astellas Pharma; Class: Antineoplastic; Mechanism of Action: Undefined mechanism; Highest Development Phase: Discontinued for Prostate cancer; Most Recent Events: 02 Nov 2012 Discontinued - Phase-I/II for Prostate cancer in United Kingdom (PO), 02 Nov 2012 Discontinued - Phase-I/II for Prostate cancer in France (PO), 02 Nov 2012 Discontinued - Phase-I/II for Prostate cancer in Belgium (PO)
|
||
|
ACTIVE MOIETY |
Results: ASP9521 showed potent inhibitory effect on enzymatic conversion from AD to T by both human AKR1C3 and cynomolgus monkey homologues in a concentration-dependent manner, with IC50 values of 11 and 49 nmol/L, respectively ASP9521 suppressed both AD-dependent PSA production and cell proliferation in LNCaP cells exogenously expressing AKR1C3 in vitro. The bioavailability of ASP9521after oral administration of 1mg/kg were 30% and 78% in rat and dog, respectively. Furthermore, ASP9521 single oral administration of 3 mg/kg suppressed AD-induced intratumoral T production in CWR22R xenografted castrate nude mice, and this inhibitory effect was maintained for 24 h. In addition, ASP9521 was rapidly eliminated from plasma after oral administration while its intratumoral concentration remained high in tumors expressing AKR1C3.
|
